Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Trial Profile

A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered With Chemotherapy Versus Chemotherapy Alone in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Jan 2019

At a glance

  • Drugs Uproleselan-sodium (Primary) ; Cytarabine; Etoposide; Fludarabine; Idarubicin; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors GlycoMimetics
  • Most Recent Events

    • 31 Dec 2018 New source identified and integrated (European Clinical Trials Database record: EudraCT2018-001076-38).
    • 19 Nov 2018 According to a GlycoMimetics media release, this trial is designed to align with guidance received from regulatory agencies.
    • 19 Nov 2018 According to a GlycoMimetics media release, the first patient in this trial has been enrolled and dosed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top